Small intestine bacterial overgrowth – SIBO. How to diagnose and treat it in the practice of the family physician according to new guidelines

Maciej Jabłkowski; Jolanta Białkowska-Warzecha; Aleksandra Jabłkowska

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2022
vol. 8

Send email

Copy url:

abstract:

Original article

Small intestine bacterial overgrowth – SIBO. How to diagnose and treat it in the practice of the family physician according to new guidelines

Maciej Jabłkowski

¹

,

Jolanta Białkowska-Warzecha

¹

,

Aleksandra Jabłkowska

¹

Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Oddział Chorób Zakaźnych i Chorób Przewodu Pokarmowego, Klinika Chorób Zakaźnych i Chorób Wątroby Uniwersytetu Medycznego w Łodzi

Lekarz POZ 1/2022

Online publish date: 2022/03/21

View full text Get citation

Small intestine bacterial overgrowth (SIBO) is a syndrome of gastrointestinal symptoms caused by excessive bacteria in the small intestine. It may result from chronic proton pump inhibitor use or accompany diseases such as IBS, diabetes mellitus, or diverticular disease. SIBO may coexist with fungal overgrowth (SIFO) or archaea overgrowth (IMO). Currently, respiratory tests are the mainstay of SIBO diagnosis. The preferred treatment is eradication of the growth with eubiotic rifaximin. A low-FODMAP diet and soluble fibre not raised bloating like arabinogalactan may be helpful for bloating and soluble fibre supplementation for constipation. Data on the use of probiotics in SIBO are inconclusive, and prokinetics are too sparse to recommend them in guidelines.

keywords:

Small intestine bacterial overgrowth – SIBO. How to diagnose and treat it in the practice of the family physician according to new guidelines

Maciej Jabłkowski 1 , Jolanta Białkowska-Warzecha 1 , Aleksandra Jabłkowska 1

SIBO, eubiosis, dysbiosis, IBS, rifaximin, guidelines

Maciej Jabłkowski

¹

,

Jolanta Białkowska-Warzecha

¹

,

Aleksandra Jabłkowska

¹